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To identify tumour and tumour-associated antigens in patients with hepatocellular carcinoma (HCC) one may find potential
diagnostic markers and immunotherapeutic targets. In the current study, 30 distinct antigens reactive with serum IgG from HCC
patients were identified by serological analysis of cDNA expression libraries (SEREX). The mRNA expression patterns of 14 of these
30 antigens were altered in cancer as further revealed by cDNA microarray, with upregulation for nine and downregulation for five
antigens. One of the upregulated antigens was cancer-testis (CT) antigen (CAGE), which had been previously reported to be
expressed exclusively in normal gametogenic tissues and aberrantly expressed in a variety of cancer cells. In our study, CAGE mRNA
was expressed in 39.4% of HCC patients, 73.3% of patients with gastric cancer and 30.8% of patients with colorectal cancer.
Antibodies against CAGE protein were detected in approximately 5.1% of the sera from HCC patients, 8.3% of that from gastric
cancer patients and 7.3% of that from colorectal cancer patients. The relative high incidence of CAGE in cancer cells makes it a
potential target for vaccine design. Another antigen of great interest is transgelin 2. The overexpression of transgelin 2 mRNA in a
large per cent (69%) of HCC points to its potential as a diagnostic marker for HCC.
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The mortality rate of hepatocellular carcinoma (HCC) is extremely
high in China and ranks the third in malignant tumours worldwide
with a global incidence of 1.2 million new cases per year. Surgery
remains the most effective treatment for HCC. However, only 20%
of HCC patients can be resected and the recurrence in resected
patients is as high as 70%. Overall, the 5-year survival for resected
patients is no more than 19%. As for therapies using chemical or
physical approaches, the outcome is still poor because of the
resistance of cancer cells in spite of some recent advances.
(Butterfield and Ribas, 2002).
Antigen-specific immunotherapy is an alternative approach for
the treatment of HCC (van der Bruggen et al, 1991). Over the past
decade, a number of clinical trials have been conducted to examine
the potential for the activation of tumour-specific T cells in HCC
patients, many have shown biological activity and a subset has
shown antitumour efficacy (Iwashita et al, 2003; Butterfield, 2004;
Kuang et al, 2004). Recent reports on clinical trial of AFP-based
vaccine indicated that spontaneous AFP-specific immunologic
responses had been induced in vaccinated HCC patients. Further
study on AFP-based immunotherapy is ongoing (Butterfield et al,
2003; Butterfield, 2004). Screening for potent tumour antigens
capable of inducing vigorous T-cell response and blocking of
tumour escape are the two major tools to improve the effectiveness
of tumour antigen vaccines. Rapid identification of tumour-
associated antigens by cytotoxic T-cell and antibody-based
screening of cDNA expression libraries has provided attractive
targets for cancer-specific immune response, which accelerates the
progress of antigen-specific immunotherapy.
Cancer-testis (CT) antigens, which express in a wide range of
different cancer types but not in normal tissues except for testis,
ovary and placenta, are considered as tumour-specific shared
antigens (Scanlan et al, 2002a). The category of CT antigens is the
common target for tumour immunotherapy in clinical trials, for
example, NY-ESO-1 is a potent CT antigen and its eliciting
integrated cellular and humoral responses have been observed in
vaccinated patients in clinical trials, with little or no toxicity (Jager
et al, 2000; Chen et al, 2004; Davis et al, 2004). The spontaneous
CD8
þ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in
HCC has been reported by our group (Shang et al, 2004), and our
application for clinical trial of NY-ESO-1b peptide vaccine for the
immunotherapy in HCC patients is under way.
In an attempt to screen for potent tumour antigens expressed in
HCC, serological analysis of cDNA expression libraries (SEREX)
has been used to screen a newly constructed HCC expression
library. A subset of 30 antigens was found to be associated with an
HCC-related serological response, and 14 of these 30 antigens
showed altered mRNA expression in HCC. The identification of
these tumour antigens provided candidates for immunological
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tumorigenesis.
MATERIALS AND METHODS
Tissue specimens and sera
The cancer tissues, adjacent noncancerous tissues and sera were
collected from Peking University teaching hospitals and the
Resource Bank of Cancer Center, Sun Yat-Sen University with
the informed consent of patients. Tissue samples were resected and
frozen immediately in liquid nitrogen. Serum samples were
collected and reserved at  701C.
Construction and immunoscreening of cDNA expression
library
Total RNAs were extracted from two moderately differentiated
HCC specimens with Trizol reagent (Life Technologies, Gaithers-
burg, MD, USA), and then mRNAs were purified by the poly-(A)
Track kit (Promega, Madison, WI, USA) and mixed at an equal
ratio. The HCC library was constructed and screened as described
before (Wang et al, 2004).
DNA sequencing
The cDNA inserts were sequenced using the BigDye Terminator
Cycle Sequencing kit (PE Applied Biosystems, Foster City, CA,
USA). The cDNA sequences were analysed using Genbank
database (http://www.ncbi.nlm.nih.gov).
cDNA microarrays
Two independent pools of RNA from tumours and the corre-
sponding noncancerous tissues were prepared by mixing aliquots
of RNA isolated from cancer tissues of six well-differentiated HCC
and their adjacent noncancerous tissues, respectively. Another two
similar pools were prepared using RNA isolated from cancer
tissues of six poorly-differentiated HCC and their adjacent
noncancerous tissues, respectively. Each pool was composed of
an equal amount of all six samples. The microarray hybridisation
was performed at the Gene Company Limited using the Human
Genome U133A GeneChip array and the Affymetrix GeneChip
platform. Analysis of microarray data was performed with the
software package of Affymetrix. In this study, the differential
expression was considered as significant between HCC and
adjacent noncancerous tissues when the ratio of signals between
the same spots on different membranes was greater than 2, with
95% confidence (Pp0.5).
Real-time quantitative reverse transcript-polymerase chain
reaction analysis (RT–PCR)
The quantitation of transcripts from 16 paired HCC and their
adjacent noncancerous tissues was performed by real-time
quantitative reverse transcript-polymerase chain reaction (RT–
PCR) (Schmittgen et al, 2000). Primers were designed using
PrimerBank Database (Wang and Seed, 2003). The emission
intensity of SYBR Green I bound to double-strand DNA was
detected with the icycler system (Bio-Rad, Hercules, CA, USA).
After an initial denaturation at 951C for 3min, the PCR reactions
were cycled 40 times as follows: 5s at 951C, 10s at the appropriate
annealing temperature and the extension duration at 721C is based
on the length of the target sequence. Fluorescence intensity was
measured at the end of each elongation phase. The melting curve
analysis was carried out immediately after amplification, following
the manufacturer’s instructions. The fold change in target gene
relative to G3PDH endogenous control was expressed as 2
 DDCt,
where DDCt¼(CtTarget CtG3PDH)T (CtTarget CtG3PDH)N. T repre-
sents cancerous tissue and N represents adjacent tissue.
RT–PCR analysis
The expression frequency of CAGE gene was determined by RT–
PCR analysis. Total RNA from cancer tissues and paired adjacent
noncancerous tissues was extracted and treated with RNase-free
DNase before reverse transcription with Advantage RT for PCR kit
(Clontech, Palo Alto, CA, USA). RT–PCR of CAGE was performed
with 35 cycles of 30s at 941C, 25s at 601C and 30s at 721C, followed
by 7min at 721C. The sequences of paired primers were as follows:
CAGE sense, 50-ccaaagcaacaagctgcatgtc-30; CAGE antisense, 50-
tcattcagcctcccaggagttg-30.
Western blot analysis
The serological reactivity of CAGE antigen was analysed by
Western blot assay. The cDNA of CAGE was constructed into
pQE31 expression vector, which was then used to transform
Escherichia coli strain M15. The recombinant CAGE protein was
induced by 1mM IPTG. Purification of the CAGE protein with
6 His tag was performed using Ni-NTA affinity chromatography
(Qiagen).
The purified CAGE protein was resolved on 12% SDS–PAGE,
and then transferred onto a nitrocellulose membrane. The
nitrocellulose membrane was incubated with sera (1:500 dilution)
for 1h after blocking with 5% low-fat milk. After washing, the NC
membrane was incubated with alkaline phosphatase-conjugated
goat anti-human IgG (1:15000 dilution) for 1h, and then
processed for NBT/BCIP colour development.
RESULTS
SEREX defined HCC-associated antigens
Using SEREX to screen a newly constructed HCC cDNA expression
library, 52 positive clones were obtained. Sequencing analysis
showed that the 52 clones represented 30 distinct antigens
(Table 1). Of these 30 antigens, one is the CT antigen CAGE
protein, and the other 13 antigens, which had previously been
reported to be involved in tumorigenesis or suspected to be
involved in tumour progression, including CDC37 (Stepanova et al,
2000), MIF (Li et al, 2004), galectin 4 (Huflejt and Leffler, 2004),
galectin 8 (Bidon-Wagner and Le Pennec, 2004), PINCH (Wang-
Rodriguez et al, 2002), SPRY2 (Lee et al, 2004a), HSPCA (Becker
et al, 2004; Huang et al, 2004b), transgelin 2 (Shields et al, 2002),
HDAC2 (Zhu et al, 2004), H factor (Junnikkala et al, 2000), AAT
(Huang et al, 2004a), B factor (Perou et al, 1999), PIBF (Lachmann
et al, 2004). Three other antigens (SR140 protein, SFRS2IP,
RNPC2) may be involved in the regulation of alternative mRNA
splicing, PSMA7 is related to hepatitis B and hepatitis C viral
replication (Zhang et al, 2000; Kruger et al, 2001), and the
remaining 12 antigens have no known association with cancer or
hepatitis B or hepatitis C.
Expression patterns of the mRNA transcripts encoding
tumour antigens identified by SEREX from HCC
With the intention to identify HCC tumour markers, expression
patterns of the mRNA transcripts encoding serologically defined
HCC antigens in HCC samples were evaluated by cDNA
microarray analysis. Of the 30 antigens, 14 antigens showed
differential mRNA expression in HCC samples relative to the
adjacent noncancerous tissues. The mRNA expression levels of
nine antigens, CAGE, transgelin2, HDAC2, RNPC2, PSMD1,
HSPCA, PSMA7, U2-associated SR140 protein and galectin 4, were
upregulated in HCC, whereas those of the other five antigens,
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validate the cDNA microarray results, with the exception of CAGE,
as well as HSPCA and galectin 4, which have been already reported
to be overexpressed in HCC (Huang et al, 2004b; Huflejt and
Leffler, 2004), the mRNA expression levels of seven antigens out of
the remaining 11 antigens were further measured by real-time
quantitative RT–PCR. Altered mRNA expression was defined as
two-fold differences in the expression level in HCC relative to
paired adjacent noncancerous tissue. Figure 1 summarised the
quantitative RT–PCR results from 16 pairs of HCC tissues. Three
antigens including B factor, HIMAP4 and C5 had downregulated
mRNA expression in HCC relative to the adjacent noncancerous
tissue, at frequencies of 88, 56 and 50%, respectively, and four
other antigens including transgelin 2, PSMA7, HDAC2 and PSMD1
were overexpressed at frequencies of 69, 44, 44 and 38%,
respectively. Of note, transgelin 2 was overexpressed at a high
rate (69%) in HCC specimens.
Expression of CAGE in different tumour entities
CAGE is a CT antigen identified from a testis library by Cho et al
(2002). To investigate the distribution of CAGE mRNA in HCC, the
cancer tissues and paired adjacent tissues were examined by RT–
PCR. CAGE mRNA was expressed in 39.4% (13 of 33) of HCC
tissues and in 9.1% (three of 33) of HCC adjacent noncancerous
tissues. Representative results are shown in Figure 2. In gastric
cancer, CAGE mRNA was detected in 73.3% (11 of 15) of cancerous
tissues and in 33.3% (five of 15) of noncancerous tissues. In
colorectal cancer, the CAGE mRNA expression rate was 30.8%
(four of 13) and 15.4% (two of 13), respectively.
Serological reactivity of recombinant CAGE protein in
cancer patients
To determine the anti-CAGE antibodies produced in tumour
patients, sera collected from patients with HCC, gastric cancer or
colorectal cancer were screened by Western blot assay with the
recombinant CAGE protein. Positive reaction was detected in 5.1%
(four of 79) of HCC patients. Clinical histopathological diagnoses
were available for three of the four patients who had serum
antibody. Two patients were at stage II and one patient at stage III.
The percentage of positive reaction was 8.3% (three of 36) in
gastric cancer and 7.3% (three of 41) in colorectal cancer, and all
Table 1 Genes cloned from hepatocellular carcinoma by SEREX
No. GenBank access no. Gene Clone repeat Remark
1 NM_000186 H factor 1 4 A component of Complement System
2 NM_001710 B factor 1 A component of Complement System
3 NM_000295 AAT 1 Alpha 1-antitrypsin
4 NM_001735 C5 1 Complement component 5
5 NM_013450 BAZ2B 1 Involved in chromatin remodelling
6 NM_001527 HDAC2 1 Regulating chromatin structure
7 XM_031553 SR140 protein 5 Involved in the regulation of alternative splicing
8 NM_004719 SFRS2IP 1 Splicing pre-mRNA
9 NM_004902 RNPC2 1 Splicing factor
10 NM_016224 Sorting nexin 9 1 Involved in intracellular trafficking
11 NM_001012 RPS8 5 Ribosomal protein S8
12 NM_007065 CDC37 1 Molecular chaperone
13 NM_005348 HSPCA 1 Molecular chaperone
14 NM_002807 PSMD1 2 A non-ATPase subunit
15 NM_005176 ATP5G2 1 Subunit c of ATP synthase
16 NM_002792 PSMA7 1 Proteasome subunit, alpha-type,7
17 NM_005842 SPRY2 1 Regulating epidermal growth factor receptor/mitogen-activated protein kinase
18 NM_004987 PINCH 2 Likely involved in integrin signalling
19 NM_002415 MIF 1 Migration inhibitory factor
20 NM_014961 RIPX 4 Rap2 interacting protein 
21 NM_006499 Galectin 8 1 Involved in modulating cell–cell and cell–matrix interactions
22 NM_006149 Galectin 4 2 Involved in modulating cell–cell and cell–matrix interactions
23 NM_006346 PIBF1 1 Progesterone-induced blocking factor 1
24 NM_003564 Transgelin 2 2 Involving in cell proliferation and migration
25 XM_042860 KIAA0379 1 Hypothetical protein
26 AF543495 Melanoma-associated antigen 1 Function unknown
27 NM_016436 HCA58 2 Function unknown
28 NM_032639 FAPP2 3 Phosphoinositol 4-phosphate adaptor protein-2
29 NM_018326 HIMAP4 1 Homo sapien immunity-associated protein 4
30 AY039237 CAGE 1 CT antigen
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Figure 1 Seven differentially expressed antigens in HCC tissues
measured by real-time quantitative RT–PCR. The frequencies for each
altered gene out of 16 paired HCC are indicated on the top of each graphic
bar (shadowed bars: overexpressed genes; solid black bars: downregulated
genes).
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sthese six patients had the cancer at stage III. Representative results
were shown in Figure 3.
DISCUSSION
SEREX has been proved to be an easy and effective approach for
the identification of tumour antigens, and so far about 1200
SEREX-defined tumour antigens have been identified. Given that
the size of the SEREX-defined cancer immunome, the repertoire of
tumour antigens capable of eliciting immune response in cancer
patients, is estimated to have 4000 antigens, continued efforts in
SEREX screening should extend our understanding of tumour
antigens (Lee et al, 2004b). With the aim to identify potent
tumour-associated antigens for clinical applications, the SEREX
screening of HCC cDNA expression library was performed in
several laboratories (Stenner-Liewen et al, 2000; Wang et al, 2002;
Uemura et al, 2003). These findings imply that different tumour-
associated antigens may be identified by SEREX from distinct HCC
samples. In this study, we established a pooled cDNA library from
two patients with HCC and screened it with pooled sera. A total of
30 antigens reactive with serum IgG from HCC patients were
identified, which include 14 antigens reported to be involved in
tumorigenesis or suspected to be related to tumour progression. Of
these, one is CT antigen (CAGE), which was first reported to be
expressed in gastric cancer by Cho et al (2002) and found to be
hypomethylated in the majority specimens of human HCC (Cho
et al, 2003). Intriguingly, none of the 30 antigens overlapped with
the antigens detected by the other two groups (Stenner-Liewen
et al, 2000; Uemura et al, 2003), and only one of them (HCA58) was
identified in our previous report (Wang et al, 2002).
Knowledge in the immunogenicity and expression pattern of
serologically defined tumour antigens is critical in assessing their
relevance to cancer and their therapeutic and diagnostic potentials.
CT antigens, with restricted expression in normal gametogenic
tissues and aberrantly expressed in a wide range of cancers, are
considered to be ideal targets for cancer vaccination today. In the
present study, the expression of CT antigen CAGE in HCC was first
identified by antibody-based screening of SEREX and subsequently
found to be overexpressed at mRNA level in 39.4% (13 of 33) of
HCC specimens, 73.3% (11 of 15) of gastric cancer samples, and
30.8% (four of 13) of colorectal cancer samples. Antibody response
was detected in 5.1% (four of 79) of the HCC patients, 8.3% (three
of 36) of the gastric cancer patients and 7.3% (three of 41) of the
patients with colorectal cancer. Thus, we have confirmed the high
expression of CAGE mRNA in gastric cancer as reported by Cho
et al (2002, 2003), and revealed the intermediate expression of
CAGE in HCC and colorectal cancer. We also demonstrated that
CAGE was immunogenic to elicit antibody response in cancer
patients. As a CT antigen, CAGE might be a potential candidate for
tumour vaccine design, provided it is proved that CAGE can
induce T-cell responses.
We are aware that CAGE was detected to be expressed in minor
but substantial number of adjacent noncancerous tissue speci-
mens, 9.1% (three of 33), 33.3% (five of 15) and 15.4% (two of 13)
in adjacent noncancerous tissues of HCC, gastric cancer and
colorectal cancers, respectively. To define the cell types expressing
CAGE mRNA in the adjacent noncancerous tissues, in situ
hybridisation and histochemical staining were performed in the
consecutive slides of the HCC adjacent noncancerous tissues with
CAGE mRNA expression. Our results showed that these non-
cancerous tissues were in cirrhotic condition and some of the
cirrhotic hepatocytes expressed CAGE mRNA (data not shown). As
the cirrhosis was considered to be precancerous condition (Kanai
et al, 2004), the positive signal of CAGE mRNA in cirrhotic
hepatocytes might imply that these cells are at the transitional
stage towards the HCC. To ensure whether CAGE was expressed in
cirrhosis tissues, 19 cirrhosis samples were collected for further
analysis of the expression of CAGE mRNA, and two of the 19
samples were observed to be positive (data not shown). A recent
study by Cho and collegues has provided evidence for promoter
hypomethylation of CAGE in the premalignant stage of gastric
carcinoma and HCC (Cho et al, 2003). It is perceivable that CAGE
is associated with the progression of tumorigenesis. Thereby, it
may be worthwhile monitoring CAGE mRNA expression in
patients with liver cirrhosis and observing the probability to
develop into HCC.
In conformity with previous reports (Scanlan et al, 2002b; Wang
et al, 2002) that a subset of antigens with cancer-related serological
profile was encoded by the genes of altered expression, in this
study, 14 of the antigens associated with an HCC-related
serological response showed altered levels of mRNA expression,
including five antigens, HIMAP4 , B factor, C5, AAT and H factor,
which had a lower level of mRNA expression in HCC relative to the
adjacent noncancerous tissues. AAT was found to inhibit
angiogenesis and tumour growth, its downregulation in cancer
may associate with tumour progression (Huang et al, 2004a). Four
other antigens associate with the inhibition of immune responses,
and hence may facilitate tumour escaping.
Nine of the antigens associated with an HCC-related serological
response, CAGE, SR140 protein, HSPCA, PSMD1, HDAC2, RNPC2,
galectin 4, transgelin 2 and PSMA7, were overexpressed in HCC.
CAGE
G3PDH
700 bp
500 bp
400 bp
700 bp
500 bp
400 bp
M Adj Ca Ca Ca Ca Ca Adj Adj Adj Adj
Figure 2 Expression of CAGE in representative HCC samples and
paired adjacent noncancerous tissues by RT–PCR. CAGE was detected in
three HCC tissues as a 529-bp PCR product. The expression of CAGE was
negative in five paired adjacent noncancerous tissues. RT–PCR for G3PDH
was used to monitor the quality of the RNA sample with a 452-bp PCR
product (Ca: cancerous tissues; Adj: adjacent noncancerous tissues; M:
marker).
80.9 kDa
63.8 kDa
49.5 kDa
37.4 kDa
26.0 kDa
13 12 11 10 9 8 7 6 5 4 3 2 1
Figure 3 Serological reactivity of the recombinant CAGE protein in
HCC patients by Western blot assay. Lane 13: protein marker; lanes 11–
12: negative controls with normal sera; lane 10: positive control with the
pooled sera, with which the HCC cDNA expression library was
immunoscreened; lane 4: positive reaction with an HCC serum; lanes 1–
3 and 5–9: negative reaction with HCC sera.
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gastric cancer (Ryu et al, 2003), was found to be upregulated in 11
of 16 HCC patients. This protein is thought to be involved in cell
proliferation and migration, suggesting that its overexpression
may be implicated in tumour progression. The fact that transgelin
2 was overexpressed and detected at a high rate (69%) in HCC
specimens has made this molecule a candidate HCC marker for
diagnosis. HDAC2, which is considered as a key element in the
dynamic regulation of many genes regulating cellular proliferation
and differentiation during carcinogenesis (Cress and Seto, 2000),
was found to be upregulated in seven of 16 HCC patients,
suggesting that its overexpression may have aetiologic significance.
A recent report showed that elevated HDAC2 mRNA expression
was observed in 82% of 57 human colonic cancer patients (Zhu
et al, 2004). In addition, a large number of studies have shown that
HDAC inhibitors can effectively arrest and revert transformation
of some cells and block the formation of tumours in rodent
models. These observations suggest that HDAC inhibitors may be
candidate drugs in therapy for human cancer (Cress and Seto,
2000). PSMA7, which was found to be overexpressed in seven of 16
HCC patients, is a subunit of proteasome, and has been shown to
interact specifically with the hepatitis B virusxprotein, a protein
critical to viral replication (Zhang et al, 2000). It is also involved in
regulating hepatitis virus C internal ribosome entry site activity,
which is essential for viral replication (Kruger et al, 2001). In
consideration of the close correlation of hepatitis with HCC,
upregulation of PSMA7 in HCC may play an important role in
aetiopathogenesis of HCC. PSMD1, which is involved in processing
of class 1 MHC peptide (Coux et al, 1996), was found to be
overexpressed in six of 16 HCC patients. However, its association
with tumour is less obvious. Transcripts encoding 2 other antigens
with cancer-related serological profiles, HSPCA and galectin 4,
have been reported to be overexpressed in 45% (20 of 45) (Huang
et al, 2004b) and 80% (four of five) (Kondoh et al, 1999) in HCC
patients, respectively; their upregulation in HCC may associate
with occurrence and progression of tumour. As regulator for pre-
mRNA splicing, overexpression of RNPC2 and SR140 protein may
also be of aetiological significance in HCC.
In the attempt to find HCC tumour markers among our SEREX-
identified 30 antigens, the mRNA expression level was quantita-
tively measured by cDNA microarray and real-time PCR, and there
were nine genes upregulated, five genes downregulated and 16
genes unaltered. These results indicate that the immunogenicity of
autoantigens in cancer patients is not closely correlated with their
mRNA expression levels. An immune response to apparently
unaltered gene products in cancer patients might be due to the
crossreaction of the antibodies generated against the mutated
product in cancer patients with the unaltered wild-type gene
product (Scanlan et al, 1998). Alternatively, the bystanding help
effect in cancer patients may activate autoantigens to induce
antibody response.
Overall, our SEREX-identified new tumour antigens in HCC add
more information in HCC immunome, which may help in
understanding the HCC tumorigenesis. And the SEREX-defined
CT antigen CAGE in HCC may be a potential candidate for tumour
vaccine design and transgelin 2 might be an HCC tumour marker
for diagnosis.
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